The landscape of U.S. equities is abuzz with anticipation as artificial intelligence (AI) cements its place as a transformative force in the technology sector. In a recent analysis by$ゴールドマン・サックス・グループ(GS.US)$, optimism for AI integration remains robust, yet valuations steer clear of the vertiginous heights of previous market bubbles. Goldman Sachs' insights reveal that market-implied long-term growth expectations hav...
Illumina's declining share price indicates market disappointment with its growth. The company's unprofitability and low revenue growth are seen as risky. Poor performance over the past year suggests unresolved challenges, and long-term share price weakness could be a bad sign. However, contrarian investors might see potential for a turnaround.
Given the liabilities on Illumina's balance sheet, relative to cash, and the company's EBIT loss over the last year, the existence of any debt seems unwise. The lack of profitability and decreasing revenue indicate a risk-averse environment for investors.
Jim Cramer on Thursday gave his take on the worst performers in the Nasdaq-100 in 2023. $モデルナ(MRNA.US)$: Cramer noted that this pharmaceutical giant was also one of the bottom stocks on the S&P 500 last year, suggesting it may still be suffering from a post-Covid hangover. $イルミナ(ILMN.US)$: Cramer likened this diagnostic equipment manufacturer to Moderna, a company that saw success during the pandemic but has since "failed t...
Despite disappointing revenue growth, Illumina's future prospects keep investors hopeful and willing to pay a high P/S ratio. Assuming stable future revenues, the share price isn't expected to drastically fall soon.
Illumina's divestment of the Grail is seen as a move to regain investor confidence, in spite of the loss-making Grail having negatively impacted Illumina's earnings.
Morning Movers Gapping up $イルミナ(ILMN.US)$shares rose by 5.33% in premarket trading in New York on Monday, after the gene-sequencing device maker said it will offload cancer screening start-up Grail. In a statement on Sunday, San Diego-based Illumina noted that divestiture will be executed through a "third-party sale or capital markets transaction" and is expected to be finalized by the end of the second quarter of next year. $セールスフォース(CRM.US)$shares ro...
The court's ruling is seen as a 'major win' for the FTC in a vertical merger case. Despite setbacks, Illumina could get another chance to argue their strategy if it continues to battle in court.
Chen Kiat : Very informative